ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

NIH Plans Grants For Those Who Barely Miss Payline

April 19, 1991

Proposed HHS Conflict of Interest Rules May Require More Disclosure by Researchers

May 15, 2009

NCI Selects 15 Awardees to Operate the Cancer Information Service.

January 7, 2005

Tight Budget, Turf Battles Kill One Project, Threaten Popular CGP Clinical Trials Effort

July 4, 1986

Degarelix Approved For Advanced Prostate Cancer

January 30, 2009

Myriad In Partnership To Market Products.

December 14, 2001